Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.72 |
| ▸ | CA2 | P00918 | 3/20 | 0.72 |
| ▸ | CA12 | O43570 | 2/20 | 0.72 |
| ▸ | CA7 | P43166 | 2/20 | 0.72 |
| ▸ | CA9 | Q16790 | 2/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl 2-Hydroxy-5-Methoxybenzoate SCHEMBL29709382 | 1.00 | CA1 (0.72) | CA1CA2CA12CA7CA9 | |
| Methyl 2-Hydroxy-5-Methoxybenzoate SCHEMBL15767832 | 0.93 | CA12 (0.64) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27444678 | 0.85 | CA12 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL294143 | 0.85 | CA12 (0.72) | CA1CA2CA12CA7CA9 | |
| SCHEMBL85785 | 0.84 | CA12 (0.62) | CA1CA2CA12CA7CA9 | |
| Methyl 2,5-Dihydroxybenzoate SCHEMBL29457577 | 0.84 | CA12 (1.00) | CA1CA2CA12CA7CA9 | |
| Methyl 2,5-Dihydroxybenzoate SCHEMBL38890 | 0.84 | CA12 (1.00) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28093168 | 0.84 | RAB9A (0.71) | KDM4ECYP1A2CYP2C19CYP2D6NPC1 | |
| SCHEMBL382822 | 0.84 | KDM4E (0.66) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4614728 | 0.84 | HPGD (0.54) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118240886-A | Method for synthesizing ethyl salicylate compound by biological enzyme catalysis | 济南大学 | 2024-06-25 | — | — | CN | claimed |
| CN-112573999-B | Preparation method of 3-chlorogentitol | 中国海洋大学 | 2022-09-02 | — | — | CN | claimed |
| US-10191398-B2 | Electrophotographic photoconductor, image forming apparatus, and process cartridge | RICOH COMPANY, LTD. (JP) | 2019-01-29 | — | — | US | claimed |
| US-20240277683-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| CN-118240886-A | Method for synthesizing ethyl salicylate compound by biological enzyme catalysis | 济南大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-108601353-B | Bactericidal composition | 高文作物保护公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230069963-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-09 | — | — | US | disclosed |
| CN-112979571-B | AKR1C3 selective inhibitor, preparation method and application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| US-5416066-A | FOR THE PREVENTION OF MYOCARDIAL INFARCTION OR INHIBITING MYOCARDIAL NECROSIS | KIRIN BREWERY CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| WO-1995004048-A1 | BENZOXAZINONES AND BENZOTHIAZINONES ENDOWED WITH THERAPEUTIC ACTIVITY | ITALFARMACO S.P.A. (IT) | 1995-02-09 | — | — | WO | disclosed |
| US-5290939-A | Process for the manufacture of brofaromine and analogs thereof | CIBA-GEIGY CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| WO-1993025542-A1 | BENZOXAZINONE AND BENZOTHIAZINONE DERIVATIVES HAVING CARDIOVASCULAR ACTIVITY | ITALFARMACO S.P.A. (IT) | 1993-12-23 | — | — | WO | disclosed |
| EP-0565721-A1 | 1,4-BENZOTHIAZEPINE DERIVATIVE | KANEKO, Noboru (JP) | 1993-10-20 | — | — | EP | disclosed |
| EP-0187487-B1 | BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGIC ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1990-08-29 | — | — | EP | disclosed |
| US-4703053-A | Benzothiophenes and benzofurans and antiallergic use thereof | WARNER-LAMBERT COMPANY (US) | 1987-10-27 | — | — | US | disclosed |
| US-4609739-A | Synthetic routes to benzofurans and benzothiophenes and intermediates therefor | THE UPJOHN COMPANY (US) | 1986-09-02 | — | — | US | disclosed |
| EP-0187487-A1 | Benzothiophenes and benzofurans having antiallergic activity | WARNER-LAMBERT COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277683-A1 | COMPOUNDS | SLC10A1, ABCB11, REN | CA1 827/4885CA2 466/4885CA12 279/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CA1 3083/4885CA2 1016/4885CA12 3267/4885 |
| US-20230069963-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | ZC3HAV1, ZC3HAV1L, IL5 | CA1 4449/4885CA2 2410/4885CA12 3982/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | CA1 764/4885CA2 429/4885CA12 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.